期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER-2阳性淋巴结阴性小肿块乳腺癌的临床特征与治疗策略 被引量：3

原文传递
导出
摘要 淋巴结阴性的小肿块乳腺癌（pTlabN0）复发风险极低，多项研究显示其5年无复发生存率〉90％，5年总生存率〉95％，而10年总生存率则超过90％。根据美国监测、流行病学和最终结果（SEER）数据库的统计结果，美国2004-2008年间所有诊断为乳腺癌的患者中有约24％为pTlabN0小肿块乳腺癌患者。
作者 李俏 徐兵河
机构地区 中国医学科学院北京协和医学院肿瘤医院肿瘤研究所
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第2期81-83,共3页 National Medical Journal of China
关键词 乳腺癌患者 淋巴结阴性 HER-2阳性 临床特征 肿块 治疗 无复发生存率 总生存率
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Joerger M, Thurlimann B, Huober J. Small HER2-positive, node- negative breast cancer: who should receive systemic adjuvant treatment. Ann Oneol,2011,22 :17-23.
  • 2Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue mieroarray series of node-negative breast cancers. J Clin Oncol,2008, 26: 5697-5704.
  • 3Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol,2009 ,27 :5700-5706.
  • 4Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor- positive breast cancer. J Clin Oncol,2006,24 : 3726-3734.
  • 5Cronin KA, Ravdin PM, Edwards BK. Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat,2009, 117 : 223-224.
  • 6Palmieri C, Jones A. The 2011 EBCTCG polychemotherapy overview. Lancet,2012,379 : 390-392.
  • 7Theriault RL, Litton JK, Mittendorf EA, et al. Age and survival estimates in patients who have node-negative T1 ab breast cancer by breast cancer subtype. Clin Breast Cancer,2011,11 : 325-331.
  • 8Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small ( Tlmic, T1 a, Tlb ) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat,2011,127 : 713-720.
  • 9Mook S, Knauer M, Bueno-de-Mesquita JM, et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol,2010,17 : 1406-1413.
  • 10Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol, 2005, 26: 5697-5704.

二级参考文献13

  • 1Lal P, Salazar PA, Hudis CA, et al. HER-2 sting in breast cancer alysis and fluorescence in situ hybridization: Angle-institution experience of 2,279 cases and mparison of dual-color and single-color scoring, m J Clin Pathol, 2004,121:631-636.
  • 2Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvantdocetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med,2006,354:809-820.
  • 3Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet ,2007,369:29-36.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations or human epidermal growth factor receptor 2 test- ng in breast cancer. J Clin 0ncol,2007,25:118-145.
  • 5Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol,2005 ,29 :1221-1227.
  • 6Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Patho1,2004,121:70-77.
  • 7Naber SP, Tsutsumi Y, Yin S, et al. Strategies for the analysis ofoncogene overexpression: studies of the neu oncogene in breast carcinoma. Am J Clin Pathol, 1990,94 : 125-136.
  • 8Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast eancer:elinieopathologic significance and impact on HER- 2 testing. J Clin 0ncol,2008,26:4869-4874.
  • 9Sahoo R, Chitti Babu V, Harini VV, et al. Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options. Onkologie ,2011,34:356-360.
  • 10Krishnamurti U, Hammers JL, Atem FD, et al. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Patho1,2009,22 : 1044-1048.

共引文献6

同被引文献62

引证文献3

二级引证文献10

中华医学杂志
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部